Purchase this article with an account.
Fedra Kort, Ahmed Chebil, Mejda Bouladi, Bouraoui Rim, El Matri Leila; Intravitreal Bevacizumab for choroidal neovascularization secondary to angioid streaks: five-year follow-up. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3843.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the five-year results of intravitreal bevacizumab for the treatment of choroidal neovascularization (CNV) complicating angioid streaks.
A retrospective interventional case series of 10 patients (10 eyes) with subfoveal or juxtafoveal active CNV secondary to angioid streaks treated with intravitreal bevacizumab injections (1.25mg/0.05ml), was conducted. All patients were followed-up for at least 5 years. Retreatment was given every four to six weeks in case of persistent symptoms or CNV activity on OCT. Efficacy of treatment was determined by changes in best corrected visual acuity (BCVA) and central retinal thickness on OCT.
The mean number of injections was 7.2 during the first year and 4.4 during the fifth year. The mean BCVA at baseline was 20/62 (range 20/400 to 20/32) and improved to 20/52 (range 20/160 to 20/20) at five years (p=0.052). The BCVA improved by three or more lines in three eyes (30%) and remained within two lines of baseline in seven eyes (70%). Mean central retinal thickness was 404.2µm (range 160 to 602 µm) at baseline and decreased significantly to 332.5µm (range 150 to 523µm) at five years. Intraretinal cysts persisted in 6 eyes (60%) with subfoveal CNV. No ocular or systemic complications were observed.
Our study suggests intravitreal bevacizumab to be an efficient and safe treatment for eyes with CNV secondary to angioid streaks at 5 years. Further long term studies are required to confirm these findings.
This PDF is available to Subscribers Only